Oncology

RRx-001 is an investigational small molecule inflammasome NLRP3 inhibitor and Nrf2 upregulator with antioxidant and anti-inflammatory properties.

Osemitamab is a high affinity, humanized antibody-dependent cellular cytotoxicity (ADCC)-enhanced anti-Claudin18.2 monoclonal antibody.

Most men with localized prostate cancer do not die within 15 years, whether or not they receive active surveillance or treatment.

Significantly increased risk seen for adults with moderate-to-severe versus mild atopic dermatitis.

The letter states that the application cannot be approved in its present form.

Though 295 drugs were in shortage last year, the latest number is 130; about 15 critical drug products have been scarce for a decade.

Retifanlimab is a programmed death receptor-1-blocking antibody.

Increased relative risks noted for current or recent use of oral, injected, implanted, IUD progestogen-only contraceptives.

Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.

Ulenistamab targets pancreatic adenocarcinoma upregulated factor, a tumor-specific protein.

Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.

Polypharmacy tied to increased risk for adverse treatment outcomes, such as toxicity and early treatment discontinuation.

FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF.

Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.

In subgroup analyses, lower risk was seen with cumulative dosage of 401mg or greater, or with therapy duration of 5 years or longer.

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation.

Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.

Catch up on drug news with the latest MPR podcast.

Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.